263 related articles for article (PubMed ID: 26869289)
21. FGFR3-TACC3 fusion in solid tumors: mini review.
Costa R; Carneiro BA; Taxter T; Tavora FA; Kalyan A; Pai SA; Chae YK; Giles FJ
Oncotarget; 2016 Aug; 7(34):55924-55938. PubMed ID: 27409839
[TBL] [Abstract][Full Text] [Related]
22. Non-Small Cell Lung Carcinoma With Clear Cell Features and FGFR3::TACC3 Gene Rearrangement : Clinicopathologic and Next Generation Sequencing Study of 7 Cases.
Suster D; Mackinnon AC; Ronen N; Mejbel HA; Harada S; Suster S
Am J Surg Pathol; 2024 Mar; 48(3):284-291. PubMed ID: 38084010
[TBL] [Abstract][Full Text] [Related]
23. Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.
Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Satoh Y; Ishii N; Aoki M
Mol Cancer Ther; 2015 Mar; 14(3):704-12. PubMed ID: 25589496
[TBL] [Abstract][Full Text] [Related]
24. A metabolic function of FGFR3-TACC3 gene fusions in cancer.
Frattini V; Pagnotta SM; Tala ; Fan JJ; Russo MV; Lee SB; Garofano L; Zhang J; Shi P; Lewis G; Sanson H; Frederick V; Castano AM; Cerulo L; Rolland DCM; Mall R; Mokhtari K; Elenitoba-Johnson KSJ; Sanson M; Huang X; Ceccarelli M; Lasorella A; Iavarone A
Nature; 2018 Jan; 553(7687):222-227. PubMed ID: 29323298
[TBL] [Abstract][Full Text] [Related]
25. Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations.
Lima NC; Atkinson E; Bunney TD; Katan M; Huang PH
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370101
[TBL] [Abstract][Full Text] [Related]
26. Unique signalling connectivity of FGFR3-TACC3 oncoprotein revealed by quantitative phosphoproteomics and differential network analysis.
Lombardi B; Ashford P; Moya-Garcia AA; Rust A; Crawford M; Williams SV; Knowles MA; Katan M; Orengo C; Godovac-Zimmermann J
Oncotarget; 2017 Nov; 8(61):102898-102911. PubMed ID: 29262532
[TBL] [Abstract][Full Text] [Related]
27. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
[TBL] [Abstract][Full Text] [Related]
28. Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma.
Wu Y; Jin W; Wang Q; Zhou J; Wang Y; Tan Y; Cui X; Tong F; Yang E; Wang J; Kang C
Mol Ther; 2021 Nov; 29(11):3305-3318. PubMed ID: 34274537
[TBL] [Abstract][Full Text] [Related]
29. Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.
Bielle F; Di Stefano AL; Meyronet D; Picca A; Villa C; Bernier M; Schmitt Y; Giry M; Rousseau A; Figarella-Branger D; Maurage CA; Uro-Coste E; Lasorella A; Iavarone A; Sanson M; Mokhtari K
Brain Pathol; 2018 Sep; 28(5):674-683. PubMed ID: 28976058
[TBL] [Abstract][Full Text] [Related]
30. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.
Granberg KJ; Annala M; Lehtinen B; Kesseli J; Haapasalo J; Ruusuvuori P; Yli-Harja O; Visakorpi T; Haapasalo H; Nykter M; Zhang W
Neuro Oncol; 2017 Sep; 19(9):1206-1216. PubMed ID: 28379477
[TBL] [Abstract][Full Text] [Related]
31. FGFR3-TACC3 Activates Mitochondrial Respiration via PIN4 Phosphorylation.
Cancer Discov; 2018 Feb; 8(2):139. PubMed ID: 29330265
[TBL] [Abstract][Full Text] [Related]
32. Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions.
Tamura R; Yoshihara K; Saito T; Ishimura R; MartÃnez-Ledesma JE; Xin H; Ishiguro T; Mori Y; Yamawaki K; Suda K; Sato S; Itamochi H; Motoyama T; Aoki Y; Okuda S; Casingal CR; Nakaoka H; Inoue I; Verhaak RGW; Komatsu M; Enomoto T
Oncogenesis; 2018 Jan; 7(1):4. PubMed ID: 29358619
[TBL] [Abstract][Full Text] [Related]
33. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
34. TACC3: a multi-functional protein promoting cancer cell survival and aggressiveness.
Saatci O; Sahin O
Cell Cycle; 2023; 22(23-24):2637-2655. PubMed ID: 38197196
[TBL] [Abstract][Full Text] [Related]
35. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
[TBL] [Abstract][Full Text] [Related]
36. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA
Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839
[TBL] [Abstract][Full Text] [Related]
37. Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas.
McDonald MF; Athukuri P; Anand A; Gopakumar S; Jalali A; Patel AJ; Rao G; Goodman JC; Lu HC; Mandel JJ
Neurosurg Focus; 2022 Dec; 53(6):E16. PubMed ID: 36455273
[TBL] [Abstract][Full Text] [Related]
38. Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs.
Georgescu MM; Islam MZ; Li Y; Traylor J; Nanda A
Acta Neuropathol Commun; 2021 Apr; 9(1):69. PubMed ID: 33853673
[TBL] [Abstract][Full Text] [Related]
39. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation.
Hart KC; Robertson SC; Donoghue DJ
Mol Biol Cell; 2001 Apr; 12(4):931-42. PubMed ID: 11294897
[TBL] [Abstract][Full Text] [Related]
40. Identification of a FGFR3-TACC3 fusion in esophageal cancer.
Mizukami T; Sakai K; Naruki S; Taniyama T; Horie Y; Izawa N; Tsuda T; Fujino T; Boku N; Yasuda H; Fukunaga T; Nakajima TE; Nishio K
Ann Oncol; 2017 Feb; 28(2):437-438. PubMed ID: 27771611
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
